ZOLL Wins MDR Approval for its New Zenix Monitor/Defibrillator

ZOLL has received European Union Medical Device Regulation 2017/745 (EU MDR) approval for Zenix, a clinically advanced and easy-to-use professional monitor/defibrillator.

The Zenix device redefines efficiency, clarity, and intelligence in both EMS and hospital settings, according to the company. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. It features a large, durable touchscreen and provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations.

Equipped with ZOLL’s innovative Real BVM Help and exclusive Real CPR Help technology, Zenix gives healthcare providers real-time clinical feedback to improve ventilation quality and deliver high-quality CPR.¹ The advanced technology of Zenix empowers EMS teams and hospital clinicians to make informed, confident decisions and ensure they are delivering exceptional patient care, ZOLL bigwigs claim.

“Whether you are a hospital clinician or an EMS professional, the ZOLL Zenix monitor/defibrillator is designed to work the way you work,” said Elijah White, president of ZOLL Acute Care Technology. “Zenix is our most advanced monitor/defibrillator, and yet it’s incredibly easy to use—virtually all functions of the device are accessible with three screen-touches or less. Along with the X Series, R Series, and ZOLL M2, Zenix extends ZOLL’s leadership in professional monitors/defibrillators with unique features and intuitive design.”

ZOLL, an Asahi Kasei company, develops and markets medical devices and software solutions that help advance care while increasing clinical and operational efficiencies. With products for defibrillation and cardiac monitoring, circulation enhancement and CPR feedback, supersaturated oxygen therapy, data management, ventilation, therapeutic temperature management, and sleep apnea diagnosis and treatment, ZOLL provides technologies that help clinicians, EMS and fire professionals, as well as lay rescuers, improve patient outcomes in critical cardiopulmonary conditions.

Since its 1922 founding, the Asahi Kasei Group has consistently grown through the transformation of its business portfolio to meet the evolving needs of every age. With 50,000 employees worldwide, the company provides solutions to the world’s challenges through its three business sectors of Healthcare, Homes, and Material. Its healthcare operations include devices and systems for critical care, products and services for manufacturing biotherapeutics, and a growing portfolio of specialty pharmaceuticals.

Reference
¹ Drennan et al. 10.1016/j.resuscitation.2024.110381. https://pubmed.ncbi.nlm.nih.gov/39299509/